Phase III Study of Safinamide in Parkinson's disease patients with Levodopa Induced Dyskinesia

Trial Profile

Phase III Study of Safinamide in Parkinson's disease patients with Levodopa Induced Dyskinesia

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2018 New trial record
    • 01 Mar 2018 According to the Newron Pharmaceuticals media release, this trial is anticipate to start in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top